Table 3.
Linear probability regression results of opioid misuse
| (1) Doctor shopping (N=61,477) |
(2) Pharmacy shopping (N=61,477) |
(3) Opioid prescription overlap (N=61,477) |
(4) Opioid/benzodiazepine overlap (N=61,477) |
|||||
|---|---|---|---|---|---|---|---|---|
| MEQ deciles | Coef | SE | Coef | SE | Coef | SE | Coef | SE |
| Decile 1:Ref group | -- | -- | -- | -- | -- | -- | -- | -- |
| Decile 2 (MEQ≥61.2) | −.0017 | .0010 | .0000 | .0001 | −.0003 | .0005 | −.0027*** | .0010 |
| Decile 3 (MEQ ≥81) | −.0010 | .0010 | .0000 | .0001 | .0005 | .0005 | −.0018 | .0010 |
| Decile 4 (MEQ ≥112.5) | −.0040*** | .0011 | −.0002 | .0001 | −.0003 | .0005 | .0033** | .0014 |
| Decile 5 (MEQ ≥151.2) | −.0094*** | .0011 | −.0005*** | .0001 | −.0002 | .0006 | .0014 | .0013 |
| Decile 6 (MEQ ≥240) | −.0128*** | .0013 | −.0007*** | .0002 | −.0007 | .0008 | .0088*** | .0018 |
| Decile 7 (MEQ ≥390) | .0051** | .0025 | −.0011*** | .0002 | .0008 | .0012 | .0199*** | .0024 |
| Decile 8 (MEQ ≥750) | .1048*** | .0055 | .0021*** | .0008 | .0216*** | .0026 | .0673*** | .0040 |
| Decile 9 (MEQ ≥2,228) | .1099*** | .0055 | .0049*** | .0010 | .1338*** | .0053 | .1613*** | .0054 |
| Decile 10 (MEQ ≥9,905) | .0796*** | .0048 | .0065*** | .0011 | .2488*** | .0069 | .2988*** | .0067 |
a
In each regression, other control variables include patient demographics (age, gender, and rurality), pain-related diagnoses (joint pain, back pain, neck pain, headache, fractures, visceral pain, wound/injury, neuropathy, reproductive system pain, and other pain) other diagnoses (depression, bipolar, schizophrenia, alcohol program, and drug problem), risk-adjusters of CDPS, and coordinated care organization.
b
Each regression is estimated using an ordinary least squares regression.
c
*** p<0.01, ** p<0.05